Metagenomi, Inc. Common Stock (MGX) NASDAQ
1.57
-0.07(-4.27%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.57
-0.07(-4.27%)
Currency In USD
| Previous Close | 1.64 |
| Open | 1.6 |
| Day High | 1.62 |
| Day Low | 1.56 |
| 52-Week High | 3.95 |
| 52-Week Low | 1.23 |
| Volume | 169,901 |
| Average Volume | 287,940 |
| Market Cap | 58.95M |
| PE | -0.7 |
| EPS | -2.23 |
| Moving Average 50 Days | 1.6 |
| Moving Average 200 Days | 1.91 |
| Change | -0.07 |
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
GlobeNewswire Inc.
Mar 05, 2026 9:05 PM GMT
Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug application (“IND”) in 4Q 2026 An
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
GlobeNewswire Inc.
Feb 23, 2026 9:05 PM GMT
EMERYVILLE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, tod
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
GlobeNewswire Inc.
Jan 12, 2026 1:30 PM GMT
New name reflects the Company’s strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 following MGX-001 preclinical data demonstrating curative